[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Question: Many proteins to fold correctly require chaperone proteins, which facilitates folding. E. coli is the organism that allows for cheap and fast production of protein originating from different organisms. Unfortunately, very often during the heterologous protein expression the protein of interest requires co-expression of the specific chaperon. From the following examples, which is the best way to co-express chaperone and protein of interest in E.coli?\n\nAnswer Choices:\nA. pCDF-1b with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nB. pET-28a(+) with kanamycin resistance and pGEX-T4-1 with ampicillin resistance\nC. pCDFDuet-1 with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nD.  pET-28a(+) with kanamycin resistance and pGEX-T4-1 with chloramphenicol resistance  \nE. pGEM\u00ae-T with ampicillin resistance and pCDF-1b with spectinomycin resistance\nF. pET-15b with ampicillin resistance and pET-28a(+) with kanamycin resistance.\nG. pASK-IBA3 with chloramphenicol resistance and pET-28a(+) with ampicillin resistance\nH. pCDFDuet-1 with spectinomycin resistance \nI. None of the above is correct.\nJ. pGEX-T4-1 with ampicillin resistance and pASK-IBA3 with chloramphenicol resistance"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762209437-s8mgVAeOyK5Xc1Zyx3jX",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. pCDFDuet-1 with spectinomycin resistance and pET-28a(+) with kanamycin resistance.\\n\\nRationale: these plasmids have compatible origins of replication (CDF vs ColE1) and different antibiotic markers, allowing stable co-maintenance and co-expression (both are T7-based for use in BL21(DE3)).\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating plasmid compatibility**\n\nI need to determine the best pair of a chaperone and protein of interest for expression in E. coli. The criteria include different origins of replication and antibiotic selection markers. I often see pET-based vectors using the T7 promoter, while chaperone plasmids like pG-KJE8 use either pACYC or pCDF origins. The key is ensuring plasmid compatibility. I'm considering options like pCDF-1b with spectinomycin and pET-28a with kanamycin, which seems to be a good match.**Choosing co-expression vectors**\n\nI'm evaluating the best vectors for co-expressing a chaperone and protein in E. coli. pCDFDuet-1 is ideal since it's designed for co-expression and includes two multiple cloning sites (MCS), with spectinomycin resistance and a CDF origin, making it compatible with pET-28a. However, using just pCDFDuet-1 alone wouldn't work for co-expression. Both options C (pCDFDuet-1 and pET-28a+) utilize T7 promoters, which seems acceptable, confirming that option C is the best choice for my needs.**Comparing plasmids for co-expression**\n\nI\u2019m checking the differences between pCDF-1b and pCDFDuet-1. While pCDF-1b might be a valid vector, it's less standard. The combination of pCDF-1b with spectinomycin and pET-28a with kanamycin seems okay, but the goal is to find a co-expression setup. pCDFDuet-1 paired with pET-28a is frequently highlighted in exam answers. So, I'll choose option C due to different replication origins, non-overlapping antibiotics, and compatible T7 promoters, ensuring a clear and concise justification.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating plasmid compatibility**\n\nI need to determine the best pair of a chaperone and protein of interest for expression in E. coli. The criteria include different origins of replication and antibiotic selection markers. I often see pET-based vectors using the T7 promoter, while chaperone plasmids like pG-KJE8 use either pACYC or pCDF origins. The key is ensuring plasmid compatibility. I'm considering options like pCDF-1b with spectinomycin and pET-28a with kanamycin, which seems to be a good match.**Choosing co-expression vectors**\n\nI'm evaluating the best vectors for co-expressing a chaperone and protein in E. coli. pCDFDuet-1 is ideal since it's designed for co-expression and includes two multiple cloning sites (MCS), with spectinomycin resistance and a CDF origin, making it compatible with pET-28a. However, using just pCDFDuet-1 alone wouldn't work for co-expression. Both options C (pCDFDuet-1 and pET-28a+) utilize T7 promoters, which seems acceptable, confirming that option C is the best choice for my needs.**Comparing plasmids for co-expression**\n\nI\u2019m checking the differences between pCDF-1b and pCDFDuet-1. While pCDF-1b might be a valid vector, it's less standard. The combination of pCDF-1b with spectinomycin and pET-28a with kanamycin seems okay, but the goal is to find a co-expression setup. pCDFDuet-1 paired with pET-28a is frequently highlighted in exam answers. So, I'll choose option C due to different replication origins, non-overlapping antibiotics, and compatible T7 promoters, ensuring a clear and concise justification.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCS6ujiLPp9D77ilYy6UBlYZNecdjZEgx3--ud3nnyA7aq1Lbuduqe4LN_z1-c-4Dxym50T0IwHVyXUP8unvvM2AXc3-fU36xPIOv03d0esWX6clA32vlW-1GRoWpSvTVxuCUWCwwOLN091ww6pDMwb_zWL9CnCaQy4N5IDHyh7VR834yEuwYLJ0gHa9t_PAw_caESsU8dFTBAHJRMY1MwrI_J4QQeYgBicI_fDIRu3GRm3yblWQmt5F4ObSNbyRgPNiS5vIzf3jPXXL4O1mq9X5RYpqWCO9dqwmkBD0ySk6k9pEWXVL5eoym6DFtArIC05sUPkJqwd15ZPEaRc7JYp383WkjikoOdjs_wLqaJE2OEKpjowHQmzh3VbpDZD2Rxq96Elj2o25qncCn_exK4uht8ycwOcIflPEPIDflSxnP3tkKCe7NIfeWwmmTkovsTdtGRtt852jGRotCp2cdEbVb_SQHWquGuuRO43cvDUUUfU0NpqTyTXUPlbIekAo7cQLWwgnBgI7rf9UsDciB0zK2WR_Za423VDswegauL34pXdxkXui40jlMmT_7tznRrBHkatdi_Y7Vj6eHOb0FssdhtZr5j-jYHzxjQbUck3iPYBMETGePXpcre7ycS7NDRerCmR5orU1ThgG9D2WlGBf2ZBj9SNBprXn_YfurmXxZmmCOLJOK0Mr2-0uOSnxdgt-235EiGpEgfDa2eTjAIoRLt_osrZnltKxDD---5TzBVgrR_d0lS8Mb6tZDOH-zR7cfWqz3fslMUOH9P_IPx_1zioCzKR-nNCbwVaPD8V2-HKoj9-fE-jjSa-P-8GNynu9PwNXLXcaBq5zLfJYKoei5XDGnhAGkR3XQik1XUs7nAze_8bJl5Ib4b5d4rMyU7Vi3_gaBC4x-X-6bERmpMndcj_v4TnoA8F5psJhTSzAIcPZFPpyeVZFko3uS9dA2hLP_T2wf9dOiO66ryEuPaRwoOIU7_TY6sYwiUElssyEYorOtiSp_ui2NMuORPisXqyHFSLMJdEncwR5BXwPbmpVNnSEIAQ5kAsMXgAI1wbR6L1f0wGTkJYb5GGRlLHpN_fTdCTLIOuorDAFQgjGfc4i0vfEWCtwG1kEx2XArjPQE4l-SgyMGXz78lBlt10qsGSI6AnPxb7P6O-8oDikPLBP8tl9cacyVx-QvV1TsZK6qtLSgpufh0Z4N3ZpoiYyfbjUS7ybTgtjOtsLJsszhA8FZG2qfBeTU482Oo3cREnbfA-dZn3t3IZfa2tWEL-BG7_fxTrunztfiTufSSosWUYycCLK0CIH2czIzp5w-4BXAxu90sF2cgyjQtQ-cwlDiBJDKI4FAnAm3t4cqSwf_VgNyW3OiDgkWJ9EsKgtSQ1zSMtgqowRxyp0kiAP_KD9DMGin5FiK9Ohfxqc5zArN73geqSxigwqt5YEizPp7BxNTsTcjlww0RI7WcjjxJZqD6TUeVtSpQlm363tHBdu6EBQxPjZpkf2hbK2WNFExFQ7ZUYx0u1YGtrtyB1OcL5q6r-d7ef3gYkNR92Om3Mvw_DL5gCfvPhya5piFXU_9BwIwlNpIEdaD5HvgYO2I21U8IFNM72OcHY3mHoKlLeSdPr6EOMKNaPqyr9pKsIt2zuXz9agrs0cNiXzzfQzERd7dGEOz9FfDL-Up7jV7mjbNm8Jp9LH0S1Zawuhhyxu8wcrlY6v5x72A6hBPJGRqANsrpNADIE29A9WpuDApHQTLP58gW5VZdniv9t7DOiuJ_JruYx6SpngeN2aMmpqu2IO4Muupck84Uy4ZTeBVLJvoYLBC5dN33x2BxssbmePYdQi5So9fTXYpbk3DDHvEZHMx05ZQwAq9WldoZmhf8KXoTRDUv-AtxvVEYzQ2WnTd16Lx4mF5wClT4GwJ8UqAto-eGZQFcbUgXfIkNp1NPqMxcsFcxaLppkPDpHLuevzBllLxmihSvyyKjKgAc0L07Kntcz0lhbJqawdhrFJbYasqx2CG3MBz3AwdWzcsLMEEG8MWyWwlAx7UT0GBDlJTx24vbMDuxhtmI-TEUi2DvAnRQQbSNz7aHah6HlE60j0ZWP8sKBVq2D7qgo869a6X-g0rtClY6_BpZglx4eisS9R-HUExn6IF2PHFcxDp1uNfGomFU29GdWNWtGwa4QfaKUB6hEdl9v3BcHVSkRYS1asbdwRUZjMj40J11OpXd6jQ7Sx8llyaEuXoFpKb2rVGqglFhKlBIsTlO6QFhc8GWNusvLw1ytT9Z7hfgn3ryKVJC6scmpYJWAQ6gF315RV0XeNcCSn4jwtdfIOpmb0aJzYAc6CUgY-MWnmmxjQe26WbyGZY57IZqV75l1kHyP21j_68maG9PODG068UMJNNUZOu_tr__doq07n7MYV9z8NHygfVOxAoEPVpQQv5ykh3tZLnIUfsTQST6VzBrNxGt0OAulewTrf6ujVUuHlcp-_6pP1S3fCbYG-MdTgkzSW10HtzQRUVboSEskHoMSA-xC5mRMUOs_5qK_AINby3WL9whYqFTp49bU27vZbjeC4uFx00iRfbgUC1RpCWyOx33kw70xi-kfbqnKt3Ibl4t0939f0FXLBsvS4J6BC89zWoTgKiNMtexH7OfTN9mCT9lMM5Ur3yv9o4UMNzalfMGD66Iizhg4kCOs4b33S_l_XCr0dnqtIp8iCIVx7QV6cqqFUa2_K3aCzbmBedbKKvB_1cVSxsWIn35tuYd8LK3-6mXCTpDujeP5IxwYmwaAmALTR5a9ldza97tu6qda0oKQUVWOkP8kgACfZqIP1p5opPDSkNhmK5zUBsuoo8tmrFCWASS0A0t8oJi2TEpZxdW79RvTPi79Ak0AV2cyWZd6j5Obzf1kPm9yf259MO93l8Gv93wJCMq1SsJxDS4o0UYPjLur9y5TlibwI7Zo7J3carjprzSmQ7t6u2IJAgnnsstLMcOipNpUhvp39yim7GxVmY3862fMLtFCxQs8yAQ9MQkzZBmN2-hifBU_9Jo8wJE6RCziruONgOJFRxzLlnia5vDQWixvWzxi95ogdh_hHiaPxCyUluESsM-Y_kZqtIZCXiOuezpZkXo4Ee_pcZpueLZFqdlJNdkfsIjdafHSTRQLOIQfwQ9w592Sb-cwDNKMacCqIYd2FhZLSLZP3RX6cdi42rQjN9chnUjR9Nr5Mh8FHFmXGi7pv6AAZcviZXfz0fHWR8CFEYFxRccD7ADcRvo0Hz6V1ffkPLaXXZTAzgc2vfJDn8LfKq5YFNWfv5nvHIHNtaE7ezPilHv1a7k5tLTTf9C-X4trtryFyy8ihMJp3SMkWubJpGnSc35yz-8otEo7SgzxotVLKT5W0Tt29CCzrlY9YbDWLpHrLVdZogp8y2f8CI016ZjNKaN1u2nm5vrXfIIfnpdk4VQwjESMICM5JDLXIYEkMFnpsuWXDUCCJMWW_Go-R7g_uRvswnO9_dP46RHcwwfLNmNbZdQxsnXYo0jluOv3VUyhMc-pdnpO_yodCdHXN34tYgZ3Ub-kXXh2Tf0kR4usa3LdW5azphljJt_xKToBdCzIqZ0sMfvLV__jh_k3tBXuoU6ey8drOpKZInztlRoQr9tUsWqPyqvwHPP3k03DTrDY7g4OryvFj_cJYF29kNOWIUfy_wCoBTjN8hIMeBq5JxsBggxZ6oL0knTnVJptp2u3OIjoja2z10uFUGP0yPkO2C2ecyAfkH2rYfZItMiU_yTtUkevzofwyqmOYdHYmQ_eVp9rS2ai2yXJEtZCV-Av30gMuJFLecrhPn1UuhZAGLneLCYMA0kx4Y3taJ5sGMR9c_DBTEKlR0DY1RsjIpJC_QafiY7FAK1mgqN6oERlOyBOOCT_vZ9wU9ZIDS9rB1c6ceqn4hewHCi3uLWv4FiTKsVbINgR3hGA8n8RgBlbJZHKAO17VEE5vk3icjF4YCTS9KIiRTIZHiln5T-ne_daPP4h-G5JdI1beBkuBvcFG0wFtM_f9ia-Sq8y4qSExoQm7-fwjbSYNfr9hIxC4ksx1u9dcPXo2Eu1Go3qYg0Tm-QkXJ5NX1_Nc1IQh6meyyAxOKmPahyfb5-0974n9cllEZ-09Idi50uHSarHef_7xvs0JudlmHds7RNMnX4fK-5yJkODDfxDFVhq65pkBGAusK1E4udXtTEIpsLy77S0NbRqguUvmT5LcBJul0kbVSijrtqNjdxTSwbf92XdIaZ8ljuOyqfk4gm4C-bY8PYUuamNiOgCOCEggk5p8x2MX8nkFQlgL1rs5L0WFpzFpNLHa_oSi2L8NQuHbKd9W31Ke3lWkDLTfIEVwn9ncVicDgLdD6hcDhvdpNaOtxkwphUn-7pVltDHjynlXMCxRbPxFNQnJrOZmKd3cHd_fwZCPx3dNGjdg9NrptUdgbEArFMYe2ySSqEaQBl8PDsA==",
                "id": "rs_08594d35a3f611ef0169092ea082e8819495dd798dbf31ff37",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762209437,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 797,
        "prompt_tokens": 391,
        "total_tokens": 1188,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 704,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00169175,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.775e-05,
          "upstream_inference_completions_cost": 0.001594
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Question: Many proteins to fold correctly require chaperone proteins, which facilitates folding. E. coli is the organism that allows for cheap and fast production of protein originating from different organisms. Unfortunately, very often during the heterologous protein expression the protein of interest requires co-expression of the specific chaperon. From the following examples, which is the best way to co-express chaperone and protein of interest in E.coli?\n\nAnswer Choices:\nA. pCDF-1b with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nB. pET-28a(+) with kanamycin resistance and pGEX-T4-1 with ampicillin resistance\nC. pCDFDuet-1 with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nD.  pET-28a(+) with kanamycin resistance and pGEX-T4-1 with chloramphenicol resistance  \nE. pGEM\u00ae-T with ampicillin resistance and pCDF-1b with spectinomycin resistance\nF. pET-15b with ampicillin resistance and pET-28a(+) with kanamycin resistance.\nG. pASK-IBA3 with chloramphenicol resistance and pET-28a(+) with ampicillin resistance\nH. pCDFDuet-1 with spectinomycin resistance \nI. None of the above is correct.\nJ. pGEX-T4-1 with ampicillin resistance and pASK-IBA3 with chloramphenicol resistance"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762209438-OklrYW3wgn3bHPDHAYuF",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. pCDFDuet-1 with spectinomycin resistance and pET-28a(+) with kanamycin resistance.\\n\\nReason: pCDFDuet-1 (CloDF13 origin, spectinomycin) is compatible with pET-28a(+) (ColE1 origin, kanamycin) so they can be maintained together in E. coli and both are T7-compatible Duet/pET expression systems suitable for co-expression of a chaperone and the protein of interest.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating plasmid options for co-expression**\n\nI need to determine the best way to co-express a chaperone and a target protein in E. coli. I must consider factors like compatible origins of replication and different antibiotic resistances. Common options include pET28a with kanamycin resistance and pCDFDuet-1 with spectinomycin resistance. I think option C, using pCDFDuet-1 and pET28a, seems best because pCDFDuet-1 is designed for co-expression and is compatible with pET in the right cell line.**Justifying plasmid selection**\n\nI need to justify why option C is the best choice. pET-28a uses the ColE1 origin while pCDFDuet-1 uses the CloDF13 origin, which provides different origins for efficient replication. They also have different antibiotic resistances: kanamycin and spectinomycin, making them compatible with T7 expression. Additionally, the Duet vector allows for multi-gene expression, supporting the co-expression I want. So, I'll finalize the answer in JSON format with \"C\" and a brief justification.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating plasmid options for co-expression**\n\nI need to determine the best way to co-express a chaperone and a target protein in E. coli. I must consider factors like compatible origins of replication and different antibiotic resistances. Common options include pET28a with kanamycin resistance and pCDFDuet-1 with spectinomycin resistance. I think option C, using pCDFDuet-1 and pET28a, seems best because pCDFDuet-1 is designed for co-expression and is compatible with pET in the right cell line.**Justifying plasmid selection**\n\nI need to justify why option C is the best choice. pET-28a uses the ColE1 origin while pCDFDuet-1 uses the CloDF13 origin, which provides different origins for efficient replication. They also have different antibiotic resistances: kanamycin and spectinomycin, making them compatible with T7 expression. Additionally, the Duet vector allows for multi-gene expression, supporting the co-expression I want. So, I'll finalize the answer in JSON format with \"C\" and a brief justification.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCS6rAJ4zND671JR4apSbWhyDxBfEdfRrkmkxzZvXixBXJbcAN7VEnhA0Pz2Ldr6qac-5dNtX6WFYWe_mbETPyABqq5Yfxq-z0ivMtdN8Yuhf_kXTi0N5E7RacPU88pJ2OHJcv9d_KzV0SraUV9hmPSj4rVlmvEnc84e1yNkUl_HfJHDGgeDpFVGIuN_tRfcBlvUdFaDrgIIs99miT8pMhmD2TGR4JJTSnpVanfOTJF3SdBA_mgdy-5y-0P22fM5lGa5sZ-oGTePKDuI6GdIG8QEKlVtelNHa6Bl3vph7r3blSy6P2FPo0t18qg8RPmLdta_hBlZUnYKy8BXYRd6pGBAmB4m00MYYcvzJ8OzFQLUug9_j8PW8amN0wyQAB2QoQubeVRXbSEFTT7aFPRULJsvE_YJ5uTHExSuxI5IRwz2cg-Bp2J_T8F5iRuszgO9Qhun-I7eCYfotKRZi_PXdNbWbhQBXrwZsf0CENJpwgY5jf9DpksZE9mad7ZZ-zlVgznIzkmwoDQ9ko5oFR8AwIrbg1bZLFHEMBsRgJiK5JC78QWB5uSYlYRaQXMunyo3nnclcvH235162dR1Twtb0_2A_n9hJ-BP0-ZeS5kOYavetLiNrDnjgo-KEdvIJ_L6m708GKR3Ye04RCPWURgrgewW55wcHMoQS130uiFb8hhrooIVbWHAONUWnD2a8e4OI6yRPNljj1s651GMSGb6gez6af_UEFvvbuPsTL46DkKnIUqYHQidGUG_JqDpo0Y1E9lYaQ_w7u7hTxi9UgmL-CqaxlElqBSOc14sC-AgWS9sMEeKIUvVh5SDms_B53kJyR0-OmwbMDgCaKzeVaCgGbpeblmPOI9JLLtN0m7h3fCTcGIKqf2uBUnnPDC46BAAylW3x5SIQOeu6e5o2fx4H2Xq19TDMHNIw7lzBX8Vpf6TSqzx0hmSSQyFFsCSc-_PUFhlrbwZcN2JyJo-cGmhUe17JJknx1kqWoAmIQjGkOR8UqnCfM8SKPVsAPhYK6KGHbL7cW3KGG4Cps07W7JtaSUsfkoFcT_ynQqLr4CwOwoTTytNxoKs7WYX8kiYPLVddOyF40Vhq29ZpFK5-qF-kNf_scU-1lKKnOI5wNCas6R6xFRtytnIsvsfTcO9wetJe8emNCt_iO3UMHujlQUWErPvG2geffGSUpKRSN9yEJcvp7P7HPY9_8s3NsGx-JNgP55ohuFEE2sGs-dLdZoS5Y0nJbCCTO4sQFxt3Fq3iWTM0dP37ekjZ74irklqaQBti8nFpJrM-3wwATbvMYY3KxohEtWV2EF9NWOajrPnouZMD_cGpPHQ47Q0ChXGIl1y2zeavqZ0Gbg3E-yADkervS8mTPn5TLZX-tN07mPBSS36FD99JnqdakgZ9h16T2df5jNOJa4rLGg_x_N6eK_nNSSj9mcJ3wG1WYTJ2BjAq2iOsL4jAl0mtkUAXkDkX7QqPbAEyVVrx1DLpl7XV5CHgyuKwcRTIfkc2SvXD7yBKiwu_1FPEukPDoFpK94oWhP3Za0uoKhtkEyq9miDw3VZRrl0NSt6cDu8QANkp6KtOnxZFJwpFzCRLlcIuCWe2exkhBu9eFHmyYumzuKfUW4AiSv1ULE5JuD5205wsRdO36qkQrc9UqOF1VUuFy9THaB2JiM-vKP3TfgVQ2H7CxpUPMcQvSo3LWXtoYPl0NzyULjG-jlf1A9sFozEp-KgwwIZjzdv75bd58uvFYw8ph8TA1EvOuMPaOZq7gq0jiFGfrbEt70382t_fhDuhrGWPbOgW9Ed7ihuAU9M5rqwJg6SwAqbSj4qx6UpnlmDGmcQRk5lwpRfLmVX4PQtupneQMoR1IKKIgLfVyjtPa4NMSMjh3CF1ZpFUtYYNPD9d9-Mu_Pnj5Mt31d124Kht0nAevxNJuW25xM9mBzN0vHDi3TahH8qGCErTrPycVbBw-5t18UNGvtse1DT3WB2lf0xIwkyyYRVtIjlIjHkft7K9mbs0Zk0x5D6NIrib8U4xwMv1-BiOcsb0dJr4rwtn2vJGbAngqJRtM1-sIcz8ibhLG7aqeXTZSx2E0TmhymXSMI5UxUNSbCQqR9u72XvXawDuZ2GNZTmK5SHNcrNgVxXQmVzuNEkDhqMp4K013fV5kdSroCUXQ_b8DCmwg2AI7uklLsVcaeg9Mum6t6h2ggWSMGw6fte334t9b799VGW4kIVAUxi7Kf2HlRrrOWyD7hB1vaZ2LQiEabdj_i5vhmUHQ767YzFjEDJb_aDypTz6xe4_aSRVbRQp-i4AgChugLxciKefaVGFW60GFUC7cMaXjxUU7ERksQwTFx53awH7vGob-1u12oTpb5ySyG_wSARVDtkclgdzB-cnkO_gsktPIcpbmvVt865ru_Bc1w8tEIqACbYQ1FIkMfCxOU1EEazNOgCIiv8oe_IMfeJyiBnooaJTWpPHX87AxCG-ALm72BeMZxf96FJkn-wAstjDVKSaS8-4TZcZrU9HIpg4LkqmRASBGdJvvHEcCKbz6A8DEAVkb-KoqpXmwK8SYTUpgFsRo6zhuvNn5AUGNNbMmb_QkFVFCiUf0zYX5lT-A7b0VZc2-FeQWu4cJTyuK63ut1lDbhTkYtQ_nNBMasoTv6_8V5JCVhYhwd0P4IysDr3lssOXKQsKOBq7Zh8_xJz4MpsRx6iMS-3PGSrBJ-YKPcMtQStvAW3jDw==",
                "id": "rs_01d692427863ff9d0169092ea1870c81958f580b9924728305",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762209438,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 444,
        "prompt_tokens": 391,
        "total_tokens": 835,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 320,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00098575,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.775e-05,
          "upstream_inference_completions_cost": 0.000888
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Question: Many proteins to fold correctly require chaperone proteins, which facilitates folding. E. coli is the organism that allows for cheap and fast production of protein originating from different organisms. Unfortunately, very often during the heterologous protein expression the protein of interest requires co-expression of the specific chaperon. From the following examples, which is the best way to co-express chaperone and protein of interest in E.coli?\n\nAnswer Choices:\nA. pCDF-1b with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nB. pET-28a(+) with kanamycin resistance and pGEX-T4-1 with ampicillin resistance\nC. pCDFDuet-1 with spectinomycin resistance and pET-28a(+) with kanamycin resistance\nD.  pET-28a(+) with kanamycin resistance and pGEX-T4-1 with chloramphenicol resistance  \nE. pGEM\u00ae-T with ampicillin resistance and pCDF-1b with spectinomycin resistance\nF. pET-15b with ampicillin resistance and pET-28a(+) with kanamycin resistance.\nG. pASK-IBA3 with chloramphenicol resistance and pET-28a(+) with ampicillin resistance\nH. pCDFDuet-1 with spectinomycin resistance \nI. None of the above is correct.\nJ. pGEX-T4-1 with ampicillin resistance and pASK-IBA3 with chloramphenicol resistance"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762209438-i5ELh71KlpHrah84w3HQ",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. pCDFDuet-1 (spectinomycin) with pET-28a(+) (kanamycin). These vectors have different replication origins (CloDF13 vs ColE1) and different antibiotic markers and are both T7-based, so they are compatible for co-expression in BL21(DE3).\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Examining plasmid co-expression**\n\nI\u2019m looking into plasmids used for co-expressing proteins. Common plasmids are pACYCDuet, pCDFDuet, and pRSFDuet, each with different antibiotics. I see that pET-28a has kanamycin resistance, which pairs well with pCDFDuet that uses spectinomycin. I'm unsure about pCDF-1b's resistance. It appears pCDFDuet-1 is better for co-expression since it has T7 promoters and multiple cloning sites. The goal is to select two plasmids with different origins and antibiotic markers, making pCDFDuet-1 the best choice.**Evaluating plasmid compatibility**\n\nI'm checking other options for plasmid combinations. For option B, pET-28a (kanamycin) with pGEX-T4-1 (ampicillin) can't coexist due to incompatible origins. Option D pairs pET-28a with pGEX-T4-1 and chloramphenicol, but pGEX doesn't support that antibiotic, making it wrong. For option E, pGEM-T may not work with pET because both likely share the ColE1 origin, rendering them incompatible. Option F has the same issue with pET-15b and pET-28a, as they share origins too. Finally, option G is incorrect since pET-28a uses kanamycin, not ampicillin.**Exploring co-expression options**\n\nI'm considering using the single plasmid pCDFDuet-1, which has spectinomycin resistance. It might be able to co-express both a chaperone and a protein of interest since it has multiple MCS and utilizes T7 promoters. However, I'm wondering if it\u2019s better to use a single plasmid or two separate ones. In general, for optimal co-expression in E. coli, it's likely better to use two plasmids with compatible origins and different antibiotic markers, or to choose a Duet vector pair. Which option is truly the best?**Assessing plasmid options for co-expression**\n\nI'm looking at protocols for co-expressing chaperones, often using compatible plasmids like pG-KJE8 with a pET vector. My options feel a bit limited, but I can consider option H, which uses pCDFDuet-1 with spectinomycin resistance. This plasmid has two T7 promoters, allowing both genes to be cloned together. While it appears suitable for chaperones, I wonder if it's the \"best way\" since it\u2019s a low-copy plasmid. If I want a different promoter for the chaperone, a separate plasmid might work better. I think the exam probably expects option C, focusing on compatibility and antibiotic markers.**Evaluating option J for compatibility**\n\nNow considering option J, which pairs pGEX-T4-1 using ampicillin and pASK-IBA3 with chloramphenicol. I\u2019m wondering if they can coexist since both plasmids might have origins from ColE1. PASK might have pBR322, making them potentially incompatible. This leads me to choose option C instead. I want to provide a concise JSON response stating the answer and its reasoning. The reasoning is that option C features different origins (CloDF13 and ColE1), uses different antibiotics, and both have T7 promoters, making it a strong choice.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Examining plasmid co-expression**\n\nI\u2019m looking into plasmids used for co-expressing proteins. Common plasmids are pACYCDuet, pCDFDuet, and pRSFDuet, each with different antibiotics. I see that pET-28a has kanamycin resistance, which pairs well with pCDFDuet that uses spectinomycin. I'm unsure about pCDF-1b's resistance. It appears pCDFDuet-1 is better for co-expression since it has T7 promoters and multiple cloning sites. The goal is to select two plasmids with different origins and antibiotic markers, making pCDFDuet-1 the best choice.**Evaluating plasmid compatibility**\n\nI'm checking other options for plasmid combinations. For option B, pET-28a (kanamycin) with pGEX-T4-1 (ampicillin) can't coexist due to incompatible origins. Option D pairs pET-28a with pGEX-T4-1 and chloramphenicol, but pGEX doesn't support that antibiotic, making it wrong. For option E, pGEM-T may not work with pET because both likely share the ColE1 origin, rendering them incompatible. Option F has the same issue with pET-15b and pET-28a, as they share origins too. Finally, option G is incorrect since pET-28a uses kanamycin, not ampicillin.**Exploring co-expression options**\n\nI'm considering using the single plasmid pCDFDuet-1, which has spectinomycin resistance. It might be able to co-express both a chaperone and a protein of interest since it has multiple MCS and utilizes T7 promoters. However, I'm wondering if it\u2019s better to use a single plasmid or two separate ones. In general, for optimal co-expression in E. coli, it's likely better to use two plasmids with compatible origins and different antibiotic markers, or to choose a Duet vector pair. Which option is truly the best?**Assessing plasmid options for co-expression**\n\nI'm looking at protocols for co-expressing chaperones, often using compatible plasmids like pG-KJE8 with a pET vector. My options feel a bit limited, but I can consider option H, which uses pCDFDuet-1 with spectinomycin resistance. This plasmid has two T7 promoters, allowing both genes to be cloned together. While it appears suitable for chaperones, I wonder if it's the \"best way\" since it\u2019s a low-copy plasmid. If I want a different promoter for the chaperone, a separate plasmid might work better. I think the exam probably expects option C, focusing on compatibility and antibiotic markers.**Evaluating option J for compatibility**\n\nNow considering option J, which pairs pGEX-T4-1 using ampicillin and pASK-IBA3 with chloramphenicol. I\u2019m wondering if they can coexist since both plasmids might have origins from ColE1. PASK might have pBR322, making them potentially incompatible. This leads me to choose option C instead. I want to provide a concise JSON response stating the answer and its reasoning. The reasoning is that option C features different origins (CloDF13 and ColE1), uses different antibiotics, and both have T7 promoters, making it a strong choice.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCS7CMk5zSflMFJzldbNO3PTWMilBwSejTsVrTfOpVfHvadxqtEQNOZHRQl_PJ5uLTPHmWuCUvHiKe1KiiqviTIomHbx-U24pvFNLxbPwjSr5oo3RAbQY7NXMbgmTic8G6kGi9O7GPmEQ6WVlXSANeS-86JwAPjbaDUZHpUJtvI5-drUEz0299xmDs5CfWCZw0v_lvnItRvHXiprOGvGUE85FLd7tpFRUcnvCxRoSzShjJIsJRxFN5Yej1lE65FyGqinFTvj1NXQSLUosSvnc0QCMjiinmo8Y8yQpxQcpad1dSDd7CAqp20uBhGoBMYzr2xwsgDL02t9c1wl2tjhviVVaRImvTrSgpBz4TplhBO1EECxz9M8x7-l2G9MDfTcfGZImnZT0qeDPlqZI2rSf_FmPEbSIgbarC7gcoVgL8Usvhf0AvG1CWRH5A8D2PX3GvQHyS2lxuTLArIO2lWeqj2Bwz_Efc9oTDvo99apsIEdLTfOi-36CNxaP-0lgVrRfLIn4x52KjwTB8cV2ICY-He72Yz_AZqyyUB2KhjRRBX2puJDxH_7RVBUu_9lqgFQ9YAqFGX9dou4cosLvPj0BrAPA6KyhzFmU7-nU_9eMcasaXe-m2_tPXQRJI7EOfzgAR9aPgN7Jh1_4M5gvCm8ODcWAJQ64HJzOxsYjfUJPazPisCnjBUv7HJThQMBEQ_YbONBqhTwNy1Z3eMCvJZESQMFL57_7Vo0-1PPO-1xluIOOFREc8k-vLhv4Gn3vpWSp0IxdxXVhXYy47Jjan3rMzr6dSleaMoWDIfSDwu3YhOf9KdF9DKoAHxNNP6Jim9meJEPV_4SEO9AJ0Y0Dw-_Fd9vuyZlmzJOqi5HlqOWfJjVTLv_ycwfV1ZzVSuP6W9qpUOYJsZYUwtzWnf3EfSnTikfck_IJVEWm9KFA06SoVhQgHW39_RDlosc3TKnb7w9Mg2fcunIqFToNXTpvnzYlwVNyIDme9J1khou5ZcyNsxur_L6u8HRTzjVMIxAZNg2vWawVi9SmBeY3W5Mqv90hxVlLn_2gYa7iPkgHLuXSdH7wHlIWUlYUzhgpJzzx3Tcz0fQay0HLbCai64FwWL9-EMeM4YaHE27IeigK3xcImTTYQvlIIUMzwakH_63jbagTXEwE3_8m9pnlRXFcCwOhhr_c_LQPj9juG9UwIcxHFXH1POdOg7nK8Sqh7aAlvRhSFi2RxBKFy6jfCTb5CPnZmXAPat3hBRr1Xhg_a0d4A-EotZxlZnoSqaAsfY1fiur3dswuyCnP5C4TmSoGTHSqaZMEb2u3BkbcAYE0EqwM7GB8g9kyoshIg2L-Zz01GyDvb_3LPZ3H5Up8ofEtWkIiGabxPu1TyqKyohpDL4TTtRNtRQPkdS_YdS7FIxNtDCMru_O0RdUAX-4zfvgvsTqyT5wIdzfBE72o6aTed66h62KsYWXHuT9AmhWo1puUYjWZNI8KL-eI3fYuD2G1WR0-KcTapRNWSogJbnqIY5fXtJsiqa4iQKpOdk_ppCRwcNIebP8ahfrYKAqj6-Ww2Xl7ZObACt6_AVibIn7C-OKI3Dbg6GGFm34t7n87jn4-Dz9_859LLMymOJ0K_9i3qT-fWqAGnfWvwo-J0bHNwZEPvSteQpLpu8PNRH_ZvQTsYAVsHBkm9gM_1fn-gP8P8WK5Ss6lki3o4rSA1l6TGL3ypgZJ1cPp6C21sqa0eSu8Kt-Yl67iy-oEKtQ4NyEGAMkJPUzNnMiD5aGNGhpBhyI8tlC9aO-IzhnnLOxXakcAJcuQQUW2LgfAoovnVi9KnmZsbAYNLhpUwnbai_guXA0pUFstFEImov2xjFihi9ZekhU8U5rIRoFqw2hG-VAWfIRl7q88K2ioPdCjLySZYmGhzktShm2lgvNrxhVkwjCZ761kcCP1cc-kVaOMI_nzMzR6ghnPzV6lPP6RgdxSELRixdJkENREXT8f69ZBc2s8Yvxo3xF2G2YzRF4f10_RuyMTDxRwfhxwQczwAR20b1WGyPL2Pl67gaB0GpiFo2AWVnM2dxxnv3jSYt3uOKEqnnyga4DrLDA_y1HkUkD_ugEVfH8gthltOM3AhPRgdmX0MGOwDEpMkH9wHpgT8_iOSE7WjfEmV3e9bMHAdQrb-XtfMBOcu2x7dq_2tYYkVSmvTKHeYMkmaHph9IQrGV-CSnAvzVdvh0eEHKKZXTbrK2apVci6fKFUONNHSxWQOFwLDRoFh8SmOxhU6m6_w4UlRg-iZDCINmzB6VIwUJVCku3FzLVD7xSRiNyRipFVJN0z67SLK-jSAfizr-__0UCjmySpWR5aesWr-efSqWP7fmkVyBzSiCITNd3hSBPD9qOjVJ0hQ-6sVygq-H3GhN1hKh8DTVOpY5WniY0gn_7NQIP1bQYOIu1sr_up5mbNByA9awaQ4BFMJxCuM2MT4ZgV4QVZJsOjr9AK_SdGUbealEYiukB1CBMHYMWUjel_PXaY1aWfxlkGe-lDx1WNsMriEz-LQtEKu0fHERGW0Oqx2dVA4D8vMOE4Jk62i7cmyL8hlVon5p_45RsCxqK6SEqkHwiVl1VrAXq_b4Gu6fVmvtbsnMqyA4W1NPjZWGUsz2gl8bBdUI5E2A-aL2ax8bkQAd9yLu4RyeDHKHx3MbDIfxdDuCDOv-DlaCVPpQKEQHziAP3bZD3mbjGPR89VDr16ytM24GkkuIbfONX_d63UhBS8cnYI1F6CzQVyhVNUntMb--knspRT7ijRkXeJ8RroZO5nxrNOzeoFPh3CLlQ7fRXxHBVcrlaKmicEzbOCloVganyBu6VDHnLzzB5_7lbFI8GUOS3gl13FQygfikCiLDitMuJHi4QL0STLoqbJmdDCMMWrEiWm_-qJMkRbztbgzwXI-I6KLZJ8oS56GXeMCAakIpoQEcPeTgmjuyM2n8o9IoK8hGDdl-v9v8TM-KM0iiOJa2wMAvKYB26rtjnmD6BwwEDY3hysjgVd00JqGOTNsMltqr35dXvyopWIMNCuM2Mi30fBxpxgjc7ptLm811lV36libv9DZlG04LoskDMscJZJPQZDlLHn8UpFlyRCOuhiQ9N8cmEW7KnCRRT5CE2JlREVPlIzK9eTjADX1hwbuJtzZ0Pw8MW8gkcSfw2e5xmqqTrTa3KDT1I04udcYu9g0_N3Bhbjstpzu9IoHYmYgaR5uthp_9lyWYbsxcVTmPBgVXIQosA0PAUjDpjrgqPzmGAKxO2FjkraX_U8FGLue9FaFdNjiEI9GIvlWxeJfQJ2wZ0VG5OcawFQh9gquR4jkNyzSiprkwmU_Duhdd4RhyFIAx6NYscrskh5mPHQ8edcxq5eQD2rEtNMJ-0E_c-_iV6vcFFJxfTkTMwxWPX9XY8w8oUz5XPV9eVTG0ApQnAFUVyvAXXFU9SRHS5QQ88mKmuO6rmpwu_3-PcZfkgJx9ISIWLsP0U3QI1VtLa0vjORS8WaQv-bOhfv1NkJlR65NffI6TBZODMZhwsetFEvv96CZV0x2edqWtdb1vXvkaeNlmyGRWTKhJ54NZ3hYACdPZx5opgt0IbWsZv5Pp5IcE5RyL2mvrTpIC1DFW7uwjkWvaAPgjidfpRs5jLiw7B07M-P3BQJZIqe3ZK3OwLJ9CQI7hIYk_TtFw7RNAUDNf-6ZjfdLLW5SgefGD9JKUsomUDs-012YZ47lsOasKz1UjaRliuSLzNOSuTVFbSGNXka9CetO6waip2M3fL1mhbIf5h-_tcQK3dfuHH2043QBhhLZDmlLwGAUJls13JV2sLJ7NEvb_EoN3fj4uARtB5t1ilVI6Cma4MR5CmA7WO8wlScR9uIoy9gtzO3LD4CSF7VerEXbg8eaem1_kdUvR28mcI-dfvpLXAXk6Lxl05x0y28WCuOyMUHTeDbJ7JAOMU-a50q7rI8q2YDZXX9Z6zhnvQsnvcwelxxdn0tbIex1xBOs411P6iV50hqRYvSTZz1_6yF0wba3-wSzKJU6DswLe5AiU-xCtoktMqFVS85OtXXg-3i4Difz1nKPGYRBBTLRiCGBtGniP4Tl7yNGRkwE_AkV6h0gGf9v8ISmqSxKnjU-5wFHIV-bgI__UGIUhMFejnQLr0ebJwqtTQdYq2tToEH_b2LV29Z2c6LepCWTzMht-8FHhfpX0J3TJejsD9Xch1JOwjX2-ge5YeBKbAOFd1QW6dyC_ncwBRHFSFKa2nly0-tiss2dEY_-6ptpc9xzrC7czs9kVAbofj_YqWLUKamHbqdN3J_l-SUY5GEg6PZ0tOrln5_txL5XmcFIxR9ieiFugHbM-Oir4XvYtFBF1-6TftRG7mhAs0o6tacNKb4x-0Hlx1Vkt2iya4Fg8Joe92rezZV-Db1JOZU6BXUrfofOKdP9MT_DWUilLh0Wbzx_f_QnDql0n0SfruUJS1lzazOB3PPE-CeWXtJJ2qb2beMgyHbCMq2bp0ncbIccSyGwQixt4LSi8el-nOpprrqAeCuc_cpGndDbUVICwBcuIJmfkBBbpUCYJS5CU20tq55ItwaZZyxZkAQvWcy9A_zhR3t1Fv3hNk3-zkZTpfFM_mhQB4UCNz2ygOlIKzPgtKNHxDiQ2GenUWgL3Msz3UOT9oq7NEipKZ-VnsXtmYc1e5pQmP8W6pEzSEe9BWjXjNj3NtrD0TzE54NK788bOCHDdSdEkSXWirhdKBHSH89ZeYekli8Tt9IiaWPz-Dm_0EW2N1Nil7U8o4tWpI7PKoUmHk5JXFpiM9G3h6uWhdP5hzRsrJEkMAoPmDczlOU-2eVTOQWJE1X6etL8fYZuMa7_S8dgVNVkl7TWgkls3a6oUkP2hftJpzSVPTFw7rlAebkHMICXIwZCphENSnkhkc4fEW7yVkQWP2bdoULpBSe3VPSrgXnb6d--bU3_vLQULp1hpkMVss9W3H5IZ14lZHbF9wFAMgg7Cw8m1JGaVO2e4W7AC9k4SICMT1e_6G7Sa0uH1zU8YHvgxMqaZ401J46eu_M920u_B2IUYo-ajMgugd9g37Ow5fMdhwJ1wEcV_bAna0l0hEVMPXKXL0E73gw7tnRC7t6lXlCtEsG5fq17dFEqKbLTv51aGvDaXaKQ2kDbm5tzsRL1rkDCV2XCvlAUcN1lRIt5gmHgmfVeFetkZBcAPy-eiKNLwGVI76d1DMX0qLmnW6Jsu7kREgN7hvSl4fl20Fm-2qBL1BA4NTjiX5b8lYQKfB9LyqQg4LNbs-RYNwAM2v4guLHX6A9GNyn1dKVcQpNl2lxt68emzhKxMqjZVH37VBXD2kYP7SN_df_PUCyGBWHark2cC0xuvnAByhXUMhMel8zWygh0-wmprBXaI-B03aHOoMHjHx9mJpiYd5m1AsASN9NGet07Snb4BRGn_XIc_ZfPK7P-u-IvrxaBe7OSwAzET4e-Rwzv4UKMb2bZVqBVn4o-MeVnM9xYoZIg6cUTTYbhRfBFFAV05wGYAJsm7QR5VkhGu6SrTxY0UFJvTynKwRcqTO2u8OFCyvQgzq476O0jYWYjPWBXlod1WV_R1wr1FKOjTJufETbjmSYtzraIO4pOf6hr0zJs78ClLqvvaSnPwopK8bhUGoqTsKsWtoXeggG8V0YxP6JUQ7E-dODnvB1sG8FN-44RadkaFtvNUyFSIRru_E7U9jiswtB6ZIjOtrkEGK7XlO2sBIdMVb24ddkgP2YD1bpQzmmJU2LBZ11814g3YAE18gKd61s1ZAUd_csGokL5Z-Wo72vOciUdpFLsmFwtT6i_c7GwZ5x2jlFv_rAuNFI4vscr6ssIDvU5qXT0Njaq64IFOZYLpcIAl9wrvOkR2yiuwsAXmiDrqg9oosmk5Ra8gohgj0BZts-O2Tz1CVrI8kr9glTn7GKrxfK_XK_N0-gFQBXDcPOxuhv2DDOpa8PORJL1a1jd82Qy2cKk-3yXIOHAXC36Kn8QFbrsyzkM6MM_gQm0TTD_seETP4I6mcmKYPuIeYedaqF2e1cJHTsMMu6zdOIkRWDC8K3QePW44Bh0S4qe8MEO--SMjXB_7_U_e6mZSMR0-J7yC2Pi7JzITxk_NCqNQYSPYAopzfq3PBAWFkVlOgJRirQ10tc-SdGo6jnhQybwc_43y0nz7Oy5fWTOkGElOIra1Ngv8PcxQhH8auIFPF4w6rMs6ZQ-JaaTynIuGOAMOpFrhF69-AIBIda5JK2qcTIeza40Z1PC2q4JQ2ffoQVPtNdqOaSoXWTInVqD2N--8sdSZ7Z3eIMQsj-dK_xu5T_ulJVW4l3Z6ezZKdVXLoIXy_Ss3-yS8xZpBGGQi7zRIWVE6yDgSmO84ijc4SyciZFbV9gLCFeGJTuIAoCx6NJkbXQHrVeeEcSENxdhSNjiyBkdCbSGvKQnq8AGabp1jC5GXSFXHpxZIQEJoxpW5ez_A1UZJoRfP-jhpWTLhNp7CIE6Yx3rbPVzJbVBcBg0SNTBvo4Ym3-EJ_WZ3RM1DWE0Npjtznor1qY77hYad3cPALMvglCwNtAcGWG_pdx0h2NaXmYrCE9eKoJ_itqQUzXM3QyE4Zx4Dxwxni7vr8_c9y0c4mA_eTSeMsr276cnrSH9yD-i3g8i1iRR8X4sTh55AsMLq_fK9bpmwt-FO8p8VvUFgaz_KUFVSYCsX6etcZSd0tnb1V4rEgc6H3lIho9JMGt4Shn1GWovY2gdVq3RTfUhlQH7xV4VkweAEz8wh3-piDQe-Ic69FiT4XZR4Ywe754Gl19lL_ueKMp2Dj6KnrKKnUN_aj8bmgvqzoWTREmbC6PoDO8RVNMwBNwyxJAyqsaTiC1USIOtvZH-ysNLVk_zjYYNnytgeLGbRRQ_Sg0Y61emL5piLJzKBJoBtHEk9_reI8BSRk3bm_8wtAVfyj-XmEA0NPd85LntylDiFEVWUYOjfYUndVJ13yUixHrl6LHkxr20qdkvD3rP3ObTOqSmtUY_3S0LM1LXaRSu3joD3t2OlLB1-jzHVkdnhNCE8d9UNsbJ8iobXht5J1MUAoLgk8kyc_J8Xjx6eZAAeENHW9_xwRKZxNyWkEeocDkTIJaKDesI3v-yzn9hR9iLx21N2mjfdis8MDiyyXNHPAFUDNNGXieDm56_oNYWxDQpdb6dzcIV0limMkvc6667-VhKwg1XA6mgmY6V4ldoN4TQXZI9BfMFByyXX7fNvjV0_VuPxaGMVun4UvLNg5ugAZEc6WVR-ttRMOSl40fFg9PNAhtPx_rJbWGkR3R8nZWJi_9Iop1l4p2oQy4DcOUuwi2DOtfhUrO13zOdISehzmBslpJBzhTJZRxiIM345Yol-a5ZnY-wrdWRnJW-Z5S1LYJSEba-WdD7ljvNPjgJEWY0Nw1m88upyYiXe6o6jfJ3dvg9u6z_qIZY0g9fws8-LXuQWz-V8aqRfVgeJ0mkOpUaYDLcYzS0FsHXL8NhXXbZZBbhNC-QCY0z8EKzDhHdANS71rhC3SSvDmtl-HNxeaqury4pwf1CnyOqnr05ZF6PVmst1Z57X0wyMxCpq7lp510QR94hu_ZMWPm8j0B9Xc7aX30Shw8VYhsL66xkbE3JDgG3gOOCg7SjBqCL20nH7-RWgE0rR2Gkt6ssnA_uZZyWebuaANMm5VzB2Whe1qA3qMTzJItHYwnla_-5V_o3YlKPg96AWetfS_9nga8lAGPKkxHF8pGLst8CKWhY9UDIQJjyHBFFT3biZh10vuTgiuW41PPkQCbn95jIJQ3cxNiIf8b2mj6M6Pn6MVHAtu9PMwxRJzyCHu9uiTs8lRh9IFDP3KPkePfC7YDHtk5D4xBcrdoZG1FOzsvydTxHKFR6u7VZmKu39RNotGjlJ9vpFkOj-7zINyquPhsEEyF-D-MoiiKyTX92aVGO38sHDbXRwcixVZJsDN8OSvJcMh6dB4YciLvmxpi62sQ5szcKAVuN-I6o1Ol2X1nd6l-MgsgvhTJY_qhSsEPKzBQYzvvHNyW5ryLYlvypGZ5Wvlzr1gsWL2Fozke0MkJHl8J7VKIZsPwJSSi8--hc7_7bcdSukWS3wZeXn7Kf2mAkjta17v8yN_eg6gi3dHavR3q8Gz1SCqu0hhhJbl6hHOX0QLkyGjXuJVXBnui59wyQdqRpf1nz8yh2r7Xin6w-3f3tTktZgQ6n7QoWgn8Kl560xT1ahsHEs7oRvXhQpw3MJEdlLdL8-Pxz5I8AvX2RY63twwJ92xtA0eeUm5bVcYOaTcF2rNOIc3PmaiYNcRH77e_QRba-yY6mCQ1bEgNVSe8Ye04hlz4Ov8pyoZegupgdbv2Je5eHDLjPAsrh6lPsRLEXdp50vsurIs6Lf-RooIN8LEgUkKFWVoYnKsaA_vPf06ieri4k85-eId30QwAifFzTAsuvXt0YPwKMexN55gGSsJ06v_XnJaL2mBgXENzbff1X7UOSTIY-2UnrmBh89MXrybEc5cy8JMM1D0JzgZmSBbi8ES7bs4vF7tAD8G8utatplv5Df2npACnl41dQ0P8v7P5qfEaWqIN0VfShTMfmah_pYZIrmq-70LIBI2S-Z4MC8pJMLuT2bt-qulazBmyHXFwPoBJnf8J5B9iyke4LyoOZwdQ8o6rN6ChmnaY_OSL6NCfFlTaN-IKWPF7BvE3COOxX3om5lGp8yLEjVgMtjaTABXr_e60HZdFpCUQL_2TswwL1GOwoO6zB8VZ7Fbrhtn7vyBMCF54yN1dbC-tGZKHqWo_nM-xu2c2I0ayDNC_5BE2-6S77T-HALZPWlophWupNdIbezuHViOe_ZzvOHNfXKrAJd5axa-q6kJYFeFs8WS9HBIAKbNiJsS5icuBsPc5pdFceQ9DILhRQzxxVuw5tN9MrhZsGXTVDRzdUlit-RCScHNrAF5LurxTd4GZK7t2VZfSTOq8GFw7q8P2zV4BO3b0H2oc0gbCBOB1OTyLXniv09wErvrKpD6VpcRJzSkxOPLe2ZW7qOJ4Fl5gVg==",
                "id": "rs_0373cd77b4cc5b7a0169092ea08bd88195a7dab4ffc908b7fd",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762209438,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1749,
        "prompt_tokens": 391,
        "total_tokens": 2140,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1664,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00359575,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.775e-05,
          "upstream_inference_completions_cost": 0.003498
        }
      },
      "provider": "OpenAI"
    }
  }
]